Companies

Johnson & Johnson

5 articles

Industry NewsJohnson & Johnson / Ollin BiosciencesEndpoints News

J&J Pays Up to $3.3B for Ollin to Fill Its Retina Gap

  • Johnson & Johnson will acquire Ollin Biosciences for roughly $2.2B upfront plus up to about $1.1B in regulatory and commercial milestones; closing is expected by year-end.
  • Ollin's lead, OLN324, is a bispecific antibody for diabetic macular edema and wet AMD; the company says an early head-to-head study beat Roche's Vabysmo on anatomy and vision.
  • A separate Blackstone Life Sciences agreement provides $750M of multi-year funding for late-stage development, in exchange for payments and royalties.
PointsBased on public reports

J&J has contact lenses and surgical vision but no retinal drug, so it is buying its way into the Vabysmo/Eylea market rather than building there. Note that the Blackstone money sits outside the headline price: the real net cost and the royalty drag depend on terms we can't see. The pitch rests on Ollin's own cross-study claim against Vabysmo, and the dosing interval, not just efficacy, will decide whether retinal specialists switch.

Industry NewsJohnson & JohnsonJohnson & Johnson

J&J's Caplyta Repeats Its Bipolar Mania Win in a Second Phase 3

  • J&J said its second pivotal Phase 3 of Caplyta (lumateperone) in acute bipolar mania met the primary and key secondary endpoints.
  • The first study read out in September; together they are intended to support a US submission for mania.
  • Both trials ran three weeks, so maintenance efficacy and long-term safety are not addressed.
PointsBased on public reports

Two positive pivotal trials is what the FDA wants, and the second effect size was smaller than the first, which is worth noting for a label negotiation. Caplyta is a key piece of the Intra-Cellular deal, so this expands the addressable psychiatric market inside a crowded atypical-antipsychotic class. Differentiation will rest on tolerability versus metabolic burden rather than raw efficacy.

Industry NewsJohnson & Johnson / Protagonist TherapeuticsBioSpace

J&J and Protagonist's Icotyde improves psoriatic arthritis, but Skyrizi likely to stay ahead

  • Phase 3 ICONIC-PsA 1 met its primary endpoint: 58% of Icotyde patients reached ACR20 at week 16 versus 41% on placebo, with no new safety signals reported by J&J.
  • BMO put placebo-adjusted joint improvement at 17% versus 23% for Skyrizi in KEEPsAKE 1, saying this does not establish differentiation.
  • BMO sees oral convenience driving uptake and expects long-term share gains; Icotyde was approved for plaque psoriasis in March 2026.
PointsBased on public reports

Cross-trial comparisons are shaky, but a smaller placebo-adjusted gain than Skyrizi means Icotyde cannot win on joint efficacy. Its pitch is convenience: the first oral IL-23R peptide against an injectable incumbent. For J&J, which also sells Tremfya, the question is whether pill preference outweighs a visible efficacy gap.

Industry NewsJohnson & JohnsonEndpoints News

FDA Gives J&J's Rybrevant Faspro Accelerated Approval in Head and Neck Cancer

  • The FDA granted accelerated approval to subcutaneous amivantamab (Rybrevant Faspro) for recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum chemotherapy and a PD-(L)1 antibody; HPV-associated oropharyngeal disease is excluded.
  • It rests on a single-arm cohort of the Phase 1b/2 OrigAMI-4 study, with confirmatory trials required; the FDA called it the first new drug for this setting in a decade.
PointsBased on public reports

This is the first indication outside lung cancer for the EGFR/MET bispecific, and a single-arm response-rate approval means the Phase 3 OrigAMI-5 first-line study now carries the franchise's credibility. Cetuximab remains the comparator everyone will cite; with no randomized data, the open question is how much of the response translates into survival.

Industry NewsJohnson & Johnson / Halda TherapeuticsBioSpace

J&J's Halda-born RIPTAC hits 75% response in late-line prostate cancer

  • J&J's oral RIPTAC JNJ-6143, inherited with its roughly $3 billion Halda purchase, posted a 75% confirmed response rate (12 of 16 measurable-disease patients) in Phase 1 data at ESMO.
  • Patients had heavily pretreated metastatic castration-resistant prostate cancer, with a median of four prior therapies.
  • A 50 mg daily dose was chosen, with nausea and raised lipids most common; Phase 2 is planned.
PointsBased on public reports

Twelve responders out of sixteen is a striking line, but it is a small, early Phase 1 cut. The more useful point is for J&J's roughly $3 billion Halda purchase: a 75% response in patients with a median of four prior therapies makes Phase 2 the real test of whether this oral RIPTAC can anchor a prostate franchise.